To include your compound in the COVID-19 Resource Center, submit it here.

AZ's asthma candidate misses again in Phase III

AstraZeneca plc (LSE:AZN; NYSE:AZN) said tralokinumab (CAT-354) missed the primary endpoint in both the Phase III STRATOS 2 and TROPOS trials to treat severe uncontrolled asthma.

Read the full 268 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE